Research
Molecular
BGM1812 exhibits excellent performance in terms of half-life, stability, and solubility.
These properties suggest BGM1812 could be a viable therapeutic option.
StrongSupportsmedium confidence
BGM1812, with excellent performance in terms of half-life, stability, and solubility.
Why this rating
The performance metrics are critical for drug efficacy and are well-supported.
Source
Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment
Leilei Zong et al. · Journal of Medicinal Chemistry · 2025
DOI 10.1021/acs.jmedchem.5c01120
otherCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →